With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Developed in consultation with clinicians and patients for an enhanced user experience
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Majority of organizations are looking to increase investments in public and hybrid cloud
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Subscribe To Our Newsletter & Stay Updated
